Medicines and Healthcare Products Regulatory Agency Grants Conditional Marketing Authorization for Novavax COVID-19 Vaccine in Great Britain*
Nuvaxovid™ COVID-19 Vaccine (recombinant, adjuvanted)▼ is the first protein-based COVID-19 vaccine authorized in Great Britain Novavax and the U.K. Vaccines Taskforce previously announced an agreement for up to 60 million doses Authorization based on data including an ongoing pivotal Phase 3 trial conducted in the U.K. with almost 15,000 participants Novavax, Inc. (Nasdaq: NVAX), a […]
